Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 85 across all filing types
Latest filing 2025-07-31 Notice of Dividend Amou…
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
JOINT ANNOUNCEMENT IN RESPECT OF THE SPECIAL DIVIDEND
Notice of Dividend Amount Classification · 85% confidence The document is a joint announcement focused exclusively on details of a special dividend: payment date, tax withholding arrangements, register closure, and notice provisions for shareholders. It does not present full financial results, management discussion, or a separate report; rather it announces dividend logistics. This aligns directly with the Notice of Dividend Amount category.
2025-07-31 English
JOINT ANNOUNCEMENT RESULTS OF EXERCISE OF RIGHT OF DISSENTING SHAREHOLDERS
M&A Activity Classification · 90% confidence The document is a joint announcement concerning the implementation of a merger under the Hong Kong Takeovers Code, reporting the results of dissenting shareholders’ exercise of rights in connection with the merger. It is clearly related to an M&A transaction rather than a financial report, voting results announcement, or regulatory notice. Hence, it classifies as M&A Activity (TAR).
2025-07-23 English
JOINT ANNOUNCEMENT (1) POLL RESULTS OF THE EGM AND THE H SHAREHOLDERS' CLASS MEETING HELD ON MONDAY, 21 JULY 2025 RELATING TO THE PROPOSED CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHAR
M&A Activity Classification · 87% confidence The document is a “joint announcement” between YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the target) and Sunshine Lake Pharma Co., Ltd. (the offeror) in relation to a proposed conditional privatization merger by absorption under the Hong Kong Takeovers Code. It is not a standalone annual or interim report, nor is it merely a notice that a report is published. It provides poll results of an Extraordinary General Meeting and an H Shareholders’ Class Meeting, along with details of the proposed withdrawal of listing, special dividend, and dissenters’ rights, all in the context of a takeover/merger transaction. This clearly falls under M&A Activity (Code: TAR): announcements related to merger proposals or takeover bids.
2025-07-21 English
Documents on Display
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2025-06-29 English
LISTING BY WAY OF INTRODUCTION ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED
Regulatory Filings Classification · 81% confidence The document is a full Listing Document/prospectus for the introduction of H Shares of Sunshine Lake Pharma Co., Ltd. on the Main Board of the Hong Kong Stock Exchange. It contains comprehensive corporate, financial, legal and risk factor disclosures, expected timetable, merger details and appendix materials, typical of an IPO prospectus or listing document. There is no dedicated “Prospectus” or “IPO” category in the taxonomy; it is neither an annual, interim, earnings, audit, ESG, nor specific transaction notice like M&A announcement (TAR) alone. This falls into the general regulatory disclosure realm, so the appropriate fallback is Regulatory Filings (RNS).
2025-06-29 English
LISTING BY WAY OF INTRODUCTION OF 112,712,832 H SHARES OF RMB1.00 EACH ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED
Share Issue/Capital Change Classification · 91% confidence The document is a formal announcement by Sunshine Lake Pharma regarding the listing by way of introduction of 112,712,832 H shares on the Hong Kong Stock Exchange and details a privatization-merger arrangement and share exchange. It is not a full prospectus itself (the Listing Document is referenced separately), nor is it an earnings, annual or interim report. The content focuses on the capital structure change and share introduction rather than fundraising or M&A advisory commentary. This aligns with the “Share Issue/Capital Change” category (SHA) for announcements of new share listings, share issues, or capital structure changes.
2025-06-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.